Europe Pharmaceutical Excipients Market

The Europe Pharmaceutical Excipients Market is valued at USD 2965.4 Million in 2024 and is projected to reach a value of USD 5785.4 Million by 2035 at a CAGR (Compound Annual Growth Rate) of 6.4% between 2025 and 2035. The market is driven by rising demand for generic drugs and advancements in drug formulations.

Key Highlights

• In 2024, Western Europe dominated the market with 73.1% market share
• By Offering, the Organic chemicals is dominated the market with 69.9% market share in 2024
• Based on End User, the Oral formulation is dominated the market with 41.01% market share

Offering Overview

The Offering Segment is divided into Organic chemicals and Inorganic chemicals. Organic chemicals is divided into Oleochemicals, Carbohydrate, and Petrochemicals. The Organic Chemicals held the dominant share in 2024, accounting for significant market share of 69.9%.

The wide range of carbon-based compounds used to enhance drug formulations are categorized as organic chemicals. Growing need for drug delivery systems, such as controlled-release and targeted delivery formulations, is fueling the rise of organic chemicals. The increasing incidence of chronic illnesses and the trend toward personalized therapy, that calls for increasingly advanced excipient solutions, lend credence to this.

End User Overview

The End User Segment is divided into Oral formulation, Liquid formulation, Topical formulation, Parenteral formulation, and others. The Oral formulation held the dominant share in 2024, accounting for significant market share of 41.01%.

Oral formulation is growing due to the convenience, efficient dosage forms and patient compliance associated with oral administration. Because of its cost-effectiveness, patient compliance, and convenience, the market is expanding rapidly. Because of their established use and convenience of administration, oral formulations such as tablets and capsules dominate the market.

Regional Overview

Europe Europe Pharmaceutical Excipients market is driven by advancements in drug development, increasing prevalence of chronic diseases, and a growing emphasis on personalized medicine. Through controlled-release formulations and innovative drug delivery methods, excipients can be used to improve patient compliance as well as drug stability and bioavailability.

The Western Europe held the largest market share and is anticipated to register the highest CAGR during the forecast period. The market is driven by an aging population, increasing prevalence of chronic diseases, technological advancement in drug delivery systems, growth in the generics market, and stringent regulatory requirement for drug quality and safety. For instance, BASF SE, a German chemical company, launched Kollicoat MAE 100-55 in 2020, a new excipient for enteric coating application. The company is also invested USD 150 Million in its Ludwigshafen site to expand pharmaceutical production capacity, demonstrating its commitment to the growing market.

In Germany, Europe Pharmaceutical Excipients market is experiencing notable growth, driven by its robust pharmaceutical industry and strong focus on research and innovation. As Europes largest economy and a leading pharmaceutical producer, Germany plays a crucial role in the continents excipients market. The German Association for Pharmaceutical Science and Technology (APV) reports that excipients represent about 10-15% of the total cost of drug production, highlighting their economic importance.

Key Trends

1. Increasing use of multifunctional excipients: Multifunctional excipients are becoming integral in modern drug formulations due to their ability to improve solubility, bioavailability, and drug absorption. With the pharmaceutical industry increasingly focusing on more complex drugs, especially those with poor solubility and stability issues, multifunctional excipients offer a streamlined solution
2. Advances in drug delivery systems for biologics and biosimilars: The increasing demand for biologics and biosimilars, which have more complex molecular structures compared to small-molecule drugs, has brought about a need for specialized excipients
3. Personalized medicine and customized excipients: The rise of personalized medicine, where treatments are tailored to individual genetic profiles or specific medical conditions, has significantly impacted the excipient market

{dashboard_image}}

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Increasing demand for personalized medicine

The shift towards personalized medicine represents a transformative trend in healthcare, significantly impacting the pharmaceuticals excipients market. Personalized medicine aims to tailor drug treatments to individual patient characteristics, such as genetic profiles, lifestyle, and disease specifics, to enhance therapeutic outcomes. This approach necessitates the use of specialized excipients that can support complex drug formulation and ensure optimal delivery and efficacy. Moreover, the rise of gene therapies and RNA-based treatments further exemplifies the need for specialized excipients. These therapies often utilize advanced delivery mechanism to transport therapeutic agents into cells, requiring excipients that ensure efficient encapsulation and release of genetic materials. The growing prevalence of such innovative treatments underscore the critical role of excipients in personalized medicine, driving continued research and investments in this fields.

Advancement in Drug Delivery Technologies

The rapid advancement in drug delivery technology is opening significant opportunities for pharmaceuticals excipient manufactures. Innovation such as controlled release formulations, transdermal patches, and nanomedicine are transforming how drugs are administered and manage, creating a demand for specialized excipients that can support these cutting-edge systems.

Competitive Landscape

The Europe Pharmaceutical Excipients market is characterized by dynamic and evolving environment with several key players and their ongoing advancement. Major Players are Ashland global holdings, BASF SE, DuPont, Evonik Industries AG, Archer Daniels Midland Company, Lubrizol Corporation, Croda International, Kerry Group, Roquette Freres, Merck KGaA, and other companies. These companies focus on product innovations, mergers, and partnerships to enhance their market presence. Increasing R&D investment and the development of advanced excipients to improve drug formulations are key strategies.

Recent Market Developments

Merck KGaA invested over €300 million in a new Life Science Research Center in Germany

• In April 2024, Merck KGaA invested over €300 million in a new Life Science Research Center in Germany, aimed at accelerating biopharmaceutical product development. This advanced facility will unite research efforts across key technologies, fostering innovation and collaboration in the biopharmaceutical sector. The center is designed to enhance capabilities in drug discovery, development, and production, leveraging cutting-edge technologies to streamline and accelerate the path from research to market. This investment underscores Mercks commitment to advancing life sciences and improving global health outcomes through accelerated innovation

IFF and BASFs Pharma Solutions divisions have partnered to integrate IFFs top pharmaceutical excipient brands

• In November 2023, IFF and BASFs Pharma Solutions divisions have partnered to integrate IFFs top pharmaceutical excipient brands into BASFs ZoomLab, a virtual pharma assistant platform. This science-driven digital tool helps pharmaceutical developers quickly and accurately select the ideal excipients for new formulations. ZoomLab simplifies the process of overcoming formulation challenges by predicting the best excipient combinations, streamlining drug development. The collaboration enhances the platform’s capabilities, offering more robust excipient options and improving formulation efficiency for pharmaceutical companies

The global Europe Pharmaceutical Excipients market can be categorized as Offering, End User and Region.